Cargando…
Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer
Various molecular‐targeting drugs have markedly improved the treatment of patients with breast cancer. As yet, therapies for triple‐negative breast cancer are mainly cytotoxic agents. To investigate the novel therapy for triple‐negative breast cancer, we herein examined the effects of a new combinat...
Autores principales: | Ono, Hisako, Horinaka, Mano, Sukeno, Mamiko, Morita, Mie, Yasuda, Shusuke, Nishimoto, Emi, Konishi, Eiichi, Sakai, Toshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486178/ https://www.ncbi.nlm.nih.gov/pubmed/34288272 http://dx.doi.org/10.1111/cas.15071 |
Ejemplares similares
-
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
por: Wada, Makoto, et al.
Publicado: (2014) -
[(18) F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models
por: Tegnebratt, Tetyana, et al.
Publicado: (2013) -
Discovery of cancer-preventive juices reactivating RB functions
por: Masuda, Mitsuharu, et al.
Publicado: (2023) -
Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells
por: Horinaka, Mano, et al.
Publicado: (2014) -
Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
por: Iizuka-Ohashi, Mahiro, et al.
Publicado: (2018)